Drug intelligence / Profile preview

STM-002

Development stage: Preclinical
Lead developer: Suntec Medical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

STM-002 is a preclinical-stage cancer immunotherapy being developed by Suntec Medical. It utilizes the company's proprietary MINC (Multifunctional Immune-modulating Nanocomplex) platform, which is designed to deliver immune-modulating agents to the tumor microenvironment to stimulate a robust anti-tumor immune response. As of the latest reports, the program is in the CMC (Chemistry, Manufacturing, and Controls) development stage, with the goal of treating multiple types of cancer.

Other names: MINC nanocomplex

Beyond the preview

Go deeper on STM-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STM-002.

Explore the full profile